Results 1 to 10 of about 122,482 (118)

The Bloody Crossroads: Interactions between Periodontitis and Hematologic Diseases [PDF]

open access: yesInternational Journal of Molecular Sciences
Paulina Mertowska   +2 more
exaly   +2 more sources

Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy?

open access: yesBlood Cancer Journal, 2023
CD19 chimeric antigen receptor (CAR) T-cell therapy has shown great success against B-cell acute lymphoblastic leukemia (B-ALL). Tandem and sequential CD19/CD22 dual-target CAR T-cell therapies have been developed to reduce the possibility of CD19 ...
Sining Liu   +21 more
doaj   +1 more source

CD7-directed CAR T-cell therapy: a potential immunotherapy strategy for relapsed/refractory acute myeloid leukemia

open access: yesExperimental Hematology & Oncology, 2022
Relapsed/refractory acute myeloid leukemia (AML) patients generally have a dismal prognosis and the treatment remains challenging. Due to the expression of CD7 on 30% AML and not on normal myeloid and erythroid cells, CD7 is an attractive target for ...
Xuanqi Cao   +15 more
doaj   +1 more source

Clinical characteristics and prognostic significance of DNA methylation regulatory gene mutations in acute myeloid leukemia

open access: yesClinical Epigenetics, 2023
Background DNA methylation is a form of epigenetic modification that regulates gene expression. However, there are limited data on the comprehensive analysis of DNA methylation regulated gene mutations (DMRGM) in acute myeloid leukemia (AML) mainly ...
Xiaoyan Xu   +13 more
doaj   +1 more source

Decitabine in combination with fludarabine and cyclophosphamide as a lymphodepletion regimen followed by CD19/CD22 bispecific targeted CAR T-cell therapy significantly improves survival in relapsed/refractory B-ALL patients

open access: yesExperimental Hematology & Oncology, 2023
Relapse is a major limitation of chimeric antigen receptor (CAR) T-cell therapy. Here, we speculated that decitabine (DAC) in combination with fludarabine and cyclophosphamide (FC) as a lymphodepletion regimen may improve the efficacy of CD19/CD22 CAR T ...
Yunju Ma   +12 more
doaj   +1 more source

DLC1 deficiency at diagnosis predicts poor prognosis in acute myeloid leukemia

open access: yesExperimental Hematology & Oncology, 2022
Acute myeloid leukemia (AML) is a complex, heterogeneous malignant hematologic disease. Although multiple prognostic-related genes gave been explored in previous studies, there are still many genes whose prognostic value remains unclear. In this study, a
Xueqian Li   +7 more
doaj   +1 more source

Roles of the intestinal microbiota and microbial metabolites in acute GVHD

open access: yesExperimental Hematology & Oncology, 2021
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is one of the most curative strategies for the treatment of many hematologic malignancies and diseases. However, acute graft-versus-host disease (GVHD) limits the success of allo-HSCT.
Dandan Lin   +5 more
doaj   +1 more source

Patient‐reported physical well‐being predicts good long‐term survival of hematopoietic stem cell transplantation

open access: yesCancer Medicine
Aim This study aimed to explore the association between patient‐reported items at different time points after hematopoietic stem cell transplantation (HSCT) and long‐term survival. Methods We conducted a study with 144 allogeneic HSCT patients, following
Yin Lu   +11 more
doaj   +1 more source

The clinical characteristics and prognosis analysis of acute B-cell lymphoblastic leukemia with MEF2D fusions

open access: yesAnnals of Hematology
To investigate the clinical characteristics and prognosis of acute B-cell lymphoblastic leukemia (B-ALL) patients with MEF2D fusions. We retrospectively analyzed 15 newly diagnosed MEF2D-positive B-ALL patients admitted to The First Affiliated Hospital ...
Shuangzhu Liu   +9 more
doaj   +1 more source

Home - About - Disclaimer - Privacy